TY - JOUR
T1 - Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens
AU - Kline, Christina Leah B.
AU - Schiccitano, Angelique
AU - Zhu, Junjia
AU - Beachler, Cheryl
AU - Sheikh, Hassan
AU - Harvey, Harold
AU - Mackley, Heath
AU - McKenna, Kevin
AU - Staveley-O'Carroll, Kevin
AU - Poritz, Lisa
AU - Messaris, Evangelos
AU - Stewart, David
AU - Sivik, Jeffrey
AU - El-Deiry, Wafik S.
PY - 2014/6
Y1 - 2014/6
N2 - Introduction Therapeutic plasma 5-fluorouracil (5-FU) levels are achieved in only 20% to 30% of patients with the current practice of administering 5-FU doses based on body surface area (BSA). Alternatively, 5-FU doses can be adjusted based on 5-FU pharmacokinetic (PK) monitoring. Although benefits of PK monitoring of 5-FU in metastatic colorectal cancer (CRC) have been reported, its utility among patients with early stage disease has not been reported. Patients and Methods We retrospectively examined the effect of 5-FU PK monitoring in 84 CRC patients (49 stage IV and 35 stage II/III) receiving mFOLFOX6 (modifiedFOLFOX6; modified 5-fluorouracil, leucovorin, oxaliplatin protocol) or mFOLFIRI (modified 5-fluorouracil, leucovorin, irinotecan protocol). Forty-six of the 84 patients received 5-FU doses based on BSA and 38 received doses that were adjusted with PK monitoring. 5-FU plasma levels were measured using a nanoparticle immunoassay method. Results 5-fluorouracil PK monitoring significantly improved disease-free survival in stage II/III patients (P =.0429). There was also a trend towards improved progression-free survival among stage IV patients who had their 5-FU levels PK-monitored (P =.16). Moreover, 5-FU PK monitoring significantly reduced (P =.0437) and delayed (P =.0144) adverse effects in stage II/III patients. Toxicity occurred after the second 5-FU dose in the BSA group and after the sixth to seventh dose in the PK monitoring group. In stage IV patients, the onset of toxicities was also delayed with PK monitoring (P =.0605). Conclusion We provide evidence that PK monitoring of 5-FU is potentially beneficial for late stage and early stage CRC. These results contribute to the growing body of evidence regarding patient benefit when treatment decisions are based on the individual patient characteristics, in this case, a patients' 5-FU levels.
AB - Introduction Therapeutic plasma 5-fluorouracil (5-FU) levels are achieved in only 20% to 30% of patients with the current practice of administering 5-FU doses based on body surface area (BSA). Alternatively, 5-FU doses can be adjusted based on 5-FU pharmacokinetic (PK) monitoring. Although benefits of PK monitoring of 5-FU in metastatic colorectal cancer (CRC) have been reported, its utility among patients with early stage disease has not been reported. Patients and Methods We retrospectively examined the effect of 5-FU PK monitoring in 84 CRC patients (49 stage IV and 35 stage II/III) receiving mFOLFOX6 (modifiedFOLFOX6; modified 5-fluorouracil, leucovorin, oxaliplatin protocol) or mFOLFIRI (modified 5-fluorouracil, leucovorin, irinotecan protocol). Forty-six of the 84 patients received 5-FU doses based on BSA and 38 received doses that were adjusted with PK monitoring. 5-FU plasma levels were measured using a nanoparticle immunoassay method. Results 5-fluorouracil PK monitoring significantly improved disease-free survival in stage II/III patients (P =.0429). There was also a trend towards improved progression-free survival among stage IV patients who had their 5-FU levels PK-monitored (P =.16). Moreover, 5-FU PK monitoring significantly reduced (P =.0437) and delayed (P =.0144) adverse effects in stage II/III patients. Toxicity occurred after the second 5-FU dose in the BSA group and after the sixth to seventh dose in the PK monitoring group. In stage IV patients, the onset of toxicities was also delayed with PK monitoring (P =.0605). Conclusion We provide evidence that PK monitoring of 5-FU is potentially beneficial for late stage and early stage CRC. These results contribute to the growing body of evidence regarding patient benefit when treatment decisions are based on the individual patient characteristics, in this case, a patients' 5-FU levels.
UR - http://www.scopus.com/inward/record.url?scp=84900493896&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84900493896&partnerID=8YFLogxK
U2 - 10.1016/j.clcc.2013.11.001
DO - 10.1016/j.clcc.2013.11.001
M3 - Article
C2 - 24461492
AN - SCOPUS:84900493896
SN - 1533-0028
VL - 13
SP - 119
EP - 126
JO - Clinical Colorectal Cancer
JF - Clinical Colorectal Cancer
IS - 2
ER -